Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study of a young Palestinian woman illustrates the diagnostic and treatment challenges of ovarian steroid cell tumors, highlighting the importance of detailed examination when hormonal therapy fails.

This case report highlights a Palestinian woman with a rare ovarian steroid cell tumor, underscoring the diagnostic challenges and potential for disease progression despite treatment attempts with various chemotherapy regimens.

This study examined the most common chemotherapy side effects among patients with prostate, bladder, and testicular cancer, noting hair loss, fatigue, and decreased appetite as frequent symptoms.

This literature study reviews the consequences of hair loss due to chemotherapy and nursing care interventions but reports no new clinical results.

Scalp hypothermia can prevent chemotherapy-induced hair loss but is not suitable for all patients, and more research is needed to improve prevention methods.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This special issue contains abstracts from the ASA 40th Annual Meeting, providing an overview of various studies without reporting new primary results.

This case study reports the first Palestinian case of an ovarian steroid cell tumor with virilization in a young female, highlighting the challenges in diagnosis and varied chemotherapeutic responses.

This narrative review evaluates evidence that regional hypothermia can reduce oral, hair, eye, and nail complications from chemotherapy, but highlights the need for more research to address study limitations.

This case report describes a 24-year-old woman with a stage IIIC retiform variant of Sertoli-Leydig cell tumour, highlighting the challenges in managing this rare ovarian tumour.

This abstract discusses pellagra as a nutritional disorder characterized by a known set of symptoms but reports no new clinical findings; the authors review existing knowledge and suggest further research.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This review discusses challenges in managing cutaneous drug reactions to anticonvulsants and reports no new clinical findings; the authors emphasize the complexity of discontinuing or rechallenging suspected agents.

This case report discusses a 17-year-old in Haiti diagnosed with a rare ovarian Sertoli-Leydig tumor, emphasizing the importance of considering future fertility and psychosocial effects when managing such conditions.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

This study identified specific profiles and courses of adverse events associated with boron neutron capture therapy for head and neck cancer, suggesting differences based on the beam incidence site.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

This case report describes a patient with diffuse large B cell lymphoma who experienced temporary Beau’s lines and onycholysis while undergoing R-CHOP chemotherapy, which resolved two months after treatment ended.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.